clinical_dev

Incannex is a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for patients living with chronic diseases and significant unmet needs. Our lead candidates are currently in Phase 2/3 and Phase 2 clinical development.

Obstructive Sleep Apnea
RePOSA
Ph 2/3 Safety and Efficacy Trial
  • 560-patient, randomized, double-blind safety and efficacy study
  • Dosing started May 2024
BABE
Bioavailability Trial
  • 115-subject, bioavailability and bioequivalence study
  • Dosing completed July 2024
POC
Ph 2 Trial
  • Crossover, safety and efficacy study
  • Study completed
Generalized Anxiety Disorder
PsiGAD2
Ph 2 Dose Comparison
  • 94-patient, double-blind, safety and efficacy study
  • Dosing expected to begin 1H 2025
PsiGAD1
Ph 2 Trial
  • 73-patient, double-blind, safety and efficacy study
  • Dosing completed January 2024
Rheumatoid Arthritis
Phase 2
Ph 2 Safety and Efficacy Study
  • 128-patient, double-blind, safety and efficacy study
  • Dosing started January 2024
Phase 1
Ph 1 Safety and PK Study
  • 36-patient, Phase 1 safety and PK study
  • Study completed

Subscribe and stay connected

"*" indicates required fields